display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
Extensive stage SCLC (Es-SCLC)
Extensive stage SCLC (Es-SCLC) - 1st Line (L1)
pembrolizumab based treatment
pembrolizumab plus SoC KEYNOTE-604

Study type: